Thermo Fisher Scientific, Inc, has announced plans to establish a manufacturing facility in Nashville, TN, dedicated to the production of single-use technologies (SUT) products. This investment is in addition to the previously announced expansion to address demand in the bioprocessing market. The company says the facility will be one of the world’s largest SUT manufacturing sites, and will more than double the company’s SUT manufacturing capacity in support of its biopharma customers. The first phase of construction will be operational by the second quarter of 2022.
“Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single use platform. This has created incredible demand for our SUT products,” says Michel Lagarde, executive vice-president of Thermo Fisher Scientific. “The site in Nashville will be critical in Thermo Fisher’s global network to continue to support the biopharma industry’s work in developing life-saving biologics and vaccines.”
The Nashville site is part of Thermo Fisher’s now more than $650-million capital investment to expand its bioprocessing production capabilities across 11 manufacturing sites in North America, Europe, and Asia. Additional capacity will be added in 2021, with the completion of expansion projects in Logan, Utah; Suzhou, China; and a new SUT manufacturing site in Singapore. This additional capacity in the SUT network supports global customers. The company’s manufacturing strategy meanwhile, utilizes equivalent processes and procedures to manufacture SUT products of consistent quality, form, fit and function worldwide.
The $650-million investment program also expands global production capabilities in additional bioprocessing manufacturing networks. Capacity expansion projects in Grand Island, NY; Miami, FL.; and Inchinnan, Scotland are tracking to accelerated timelines to increase production capacity for Gibco cell culture media, supplements, and process liquids, as well as the manufacturing of customer-owned proprietary media formulations. Thermo Fisher’s purification network, which specializes in the production of process-scale chromatography resins for a variety of applications, including vaccines and gene therapies, continues to progress in capacity expansion efforts at its POROS resin manufacturing site in Bedford, Mass. Officials are nearing completion of the first phase of construction at its new site in Chelmsford, MA.
Featured image: Thermo Fisher Scientific is expanding its single use technology (SUT) manufacturing capabilities with a new site in Nashville. Thermo Fisher says the facility will be one of the world’s largest sites of its kind and will more than double the company’s SUT manufacturing capacity to support its biopharma customers. Photo: Thermo Fisher Scientific